Aphaia Pharma Headquarters: Switzerland Technology: oral glucose formulation Lead candidate: APH-012 As disruptions in the guts natural responses to food intake are linked to metabolic diseases, such as obesity, Swiss biotech company Aphaia Pharma has come up with a way to restore these said natural responses, different from conventional obesity therapies like GLP-1 agonists
Vogt BL, Richie JP Jr
Alternatives Anthem May Cover Instead of Eliquis If Eliquis is denied or placed on a tier that makes it unaffordable, your prescriber may consider: Rivaroxaban (Xarelto) Rivaroxaban is another Factor Xa inhibitor approved for AF stroke prevention, DVT/PE treatment, and DVT prevention
MiR-3926 Inhibits Synovial Fibroblasts Proliferation and Inflammatory Cytokines Secretion Through Targeting Toll Like Receptor 5
just pick a spot and stick with it
That means youre less likely to confuse GLP-1/GIP side effects like nausea, constipation, or fatigue with thyroid symptoms, and you have the Paloma team looking at the full picture rather than treating each issue separately